ETCH的个人主页 - 老虎社区

ETCH

ETCH

暂无个人介绍

IP属地：未知

17关注

13粉丝

0主题

0勋章

2021-08-11

X, CLF, NUE, AA.. all the materials stock ready toboom on this deal

抱歉，原内容已删除

2021-07-09

Like n comment pls

Meme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote>

2021-07-01

90% China market share but still unprofitable bizmodel currently, future is autonomous vehicle, if able to eliminate driver cost, will send this stock over the moon

China's Didi to be added to FTSE's equity indexes on July 8<blockquote>中国滴滴将于7月8日纳入富时股票指数</blockquote>

2021-09-10

Time is running out for market share

Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>

2021-07-29

Buy index and sleep well at night

抱歉，原内容已删除

2021-07-15

Ok nice

Microsoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote>

2021-08-04

Pfizer slow and steady NVAX roller coaster rideChoose your poison

3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>

2021-07-26

Fsly yeah

抱歉，原内容已删除

2021-07-25

Like comment pls

抱歉，原内容已删除

2021-07-25

Ok like comment

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576835084140349","uuid":"3576835084140349","gmtCreate":1613741215736,"gmtModify":1619447748457,"name":"ETCH","pinyin":"etch","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":17,"tweetSize":27,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":883490547,"gmtCreate":1631261575289,"gmtModify":1632883582121,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Time is running out for market share","listText":"Time is running out for market share","text":"Time is running out for market share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/883490547","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://www.laohu8.com/m/news/1158877090?lang=zh_CN&edition=full","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-10 15:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835449547,"gmtCreate":1629734905889,"gmtModify":1633682818406,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835449547","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":2376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892174124,"gmtCreate":1628646190368,"gmtModify":1633745432252,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","listText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","text":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/892174124","repostId":"1185123318","repostType":4,"isVote":1,"tweetType":1,"viewCount":2937,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898725902,"gmtCreate":1628523372606,"gmtModify":1633746441945,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898725902","repostId":"2158442754","repostType":4,"isVote":1,"tweetType":1,"viewCount":1561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893382601,"gmtCreate":1628238268103,"gmtModify":1633752336402,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","listText":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","text":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/893382601","repostId":"1103242546","repostType":4,"isVote":1,"tweetType":1,"viewCount":3614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890001411,"gmtCreate":1628064152233,"gmtModify":1633753926691,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","listText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","text":"Pfizer slow and steady NVAX roller coaster rideChoose your poison","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890001411","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802787592,"gmtCreate":1627808771416,"gmtModify":1633756199264,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"ok well","listText":"ok well","text":"ok well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/802787592","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":2281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806612256,"gmtCreate":1627653325275,"gmtModify":1633757405441,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Inflation rate keep climbing.. correction soon..&nbsp;","listText":"Inflation rate keep climbing.. correction soon..&nbsp;","text":"Inflation rate keep climbing.. correction soon..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806612256","repostId":"1109167679","repostType":4,"isVote":1,"tweetType":1,"viewCount":1932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801174817,"gmtCreate":1627493155939,"gmtModify":1633764458673,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Buy index and sleep well at night&nbsp;","listText":"Buy index and sleep well at night&nbsp;","text":"Buy index and sleep well at night","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/801174817","repostId":"2154918711","repostType":4,"isVote":1,"tweetType":1,"viewCount":3287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800665278,"gmtCreate":1627299121894,"gmtModify":1633766401760,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800665278","repostId":"2154570979","repostType":2,"repost":{"id":"2154570979","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627299058,"share":"https://www.laohu8.com/m/news/2154570979?lang=zh_CN&edition=full","pubTime":"2021-07-26 19:30","market":"hk","language":"en","title":"Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate<blockquote>洛克希德·马丁公司第一季度EPS$6.56超出预期$6.30，销售额$16.26 B低于预期$16.33 B</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2154570979","media":"Benzinga","summary":"Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same","content":"<p><html><body>Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.</p><p><blockquote><html><body>洛克希德·马丁公司（纽约证券交易所股票代码：LMT）报告季度收益为每股6.56美元，比分析师普遍预期的6.30美元高出4.13%。这比去年同期每股收益6.08美元增长了7.89%。该公司公布的季度销售额为162.6亿美元，比分析师普遍预期的163.3亿美元低0.44%。这比去年同期156.5亿美元的销售额增长了3.88%。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate<blockquote>洛克希德·马丁公司第一季度EPS$6.56超出预期$6.30，销售额$16.26 B低于预期$16.33 B</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate<blockquote>洛克希德·马丁公司第一季度EPS$6.56超出预期$6.30，销售额$16.26 B低于预期$16.33 B</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-07-26 19:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><html><body>Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.</p><p><blockquote><html><body>洛克希德·马丁公司（纽约证券交易所股票代码：LMT）报告季度收益为每股6.56美元，比分析师普遍预期的6.30美元高出4.13%。这比去年同期每股收益6.08美元增长了7.89%。该公司公布的季度销售额为162.6亿美元，比分析师普遍预期的163.3亿美元低0.44%。这比去年同期156.5亿美元的销售额增长了3.88%。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMT":"洛克希德马丁"},"source_url":"https://www.benzinga.com/news/earnings/21/07/22144945/lockheed-martin-q1-eps-6-56-beats-6-30-estimate-sales-16-26b-miss-16-33b-estimate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154570979","content_text":"Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.","news_type":1,"symbols_score_info":{"LMT":1}},"isVote":1,"tweetType":1,"viewCount":1997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800668518,"gmtCreate":1627298877934,"gmtModify":1633766403651,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Fsly yeah","listText":"Fsly yeah","text":"Fsly yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/800668518","repostId":"2154931205","repostType":4,"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177236555,"gmtCreate":1627221210177,"gmtModify":1633767078890,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Like comment pls","listText":"Like comment pls","text":"Like comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177236555","repostId":"2153878189","repostType":4,"isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177236148,"gmtCreate":1627221165984,"gmtModify":1633767079360,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok like comment&nbsp;","listText":"Ok like comment&nbsp;","text":"Ok like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177236148","repostId":"1115106146","repostType":4,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172698873,"gmtCreate":1626957142592,"gmtModify":1633769413357,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok gd day ahead&nbsp;","listText":"Ok gd day ahead&nbsp;","text":"Ok gd day ahead","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172698873","repostId":"1127427732","repostType":4,"repost":{"id":"1127427732","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626954531,"share":"https://www.laohu8.com/m/news/1127427732?lang=zh_CN&edition=full","pubTime":"2021-07-22 19:48","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1127427732","media":"Tiger Newspress","summary":"(Julr 22) Stock futures advanced on Thursday, with investors looking to earnings and data for impetu","content":"<p>(Julr&nbsp;22)&nbsp;Stock futures advanced on Thursday, with investors looking to earnings and data for impetus to extend a 2-day rally that wiped out losses sustained during the worst trading day of 2021.</p><p><blockquote>（7月22日）股指期货周四上涨，投资者寻求收益和数据的动力，以延续两天的涨势，抹去了2021年最糟糕交易日的跌幅。</blockquote></p><p> At 7:54 a.m. ET, Dow E-minis were up 47 points, or 0.14%, S&amp;P 500 E-minis were up 6.5&nbsp;points, or 0.15% and Nasdaq 100 E-minis rose 28.75 points, or 0.19%.&nbsp;</p><p><blockquote>截至美国东部时间上午7:54，道指E-minis上涨47点，涨幅0.14%，标普500 E-minis上涨6.5点，涨幅0.15%，纳斯达克100 E-minis上涨28.75点，涨幅0.19%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6f0ee7363c9fe8efde482515ffff79ac\" tg-width=\"1242\" tg-height=\"538\" referrerpolicy=\"no-referrer\">The turnaround from the Monday selloff shows “corporations have been very resilient through all this,”&nbsp;David Mazza, Direxion head of product, said on Bloomberg Television. “Earnings estimates are quite remarkable, probably some of the best on record. Even through all this, we have central-bank liquidity remaining very abundant, economic growth being robust.”</p><p><blockquote>Direxion产品主管David Mazza在彭博电视台表示，周一抛售的好转表明“企业在这一切中表现得非常有弹性”。“盈利预期相当出色，可能是有记录以来最好的之一。尽管如此，我们的央行流动性仍然非常充裕，经济增长强劲。”</blockquote></p><p> Energy and mega-cap tech stocks gained ahead of a new batch of earnings reports, the latest initial claims data and the first ECB meeting to incorporate the bank's new strategic review.&nbsp;Energy stocks Chevron Corp, Exxon Mobil, Schlumberger NV, Occidental Petroleum and Marathon Petroleum Corp climbed between 0.1% and 1%, tracking crude prices.</p><p><blockquote>在新一批收益报告、最新的首次申请失业救济数据以及欧洲央行首次会议纳入该行新的战略评估之前，能源股和大型科技股上涨。能源股雪佛龙公司、埃克森美孚公司、斯伦贝谢公司、西方石油公司和马拉松石油公司上涨0.1%至1%，跟踪原油价格。</blockquote></p><p> Some other notable pre-market movers:</p><p><blockquote>其他一些值得注意的盘前推动者：</blockquote></p><p> <ul>  <li>Didi Global (DIDI) drops 3% in&nbsp;premarket&nbsp;trading after people familiar with the matter said Chinese regulators are considering serious, perhaps unprecedented, penalties for for the ride-hailing giant after its controversial initial public offering last month.</li>  <li>Texas Instruments (TXN) drops 4.8% after third-quarter sales and profit forecasts left analysts disappointed, with Barclays saying the “flat outlook leaves little to live for this late in the cycle.”</li>  <li>AT&amp;T (T) added 0.9% as the telecom operator beat analysts’ estimates for monthly phone bill paying subscriber additions in the second quarter, fueled by more Americans converting to 5G phones.</li>  <li>Dow (DOW) rose 1.3% after its second-quarter profit doubled from the first, as prices for its chemicals used in plastics and packaging rose on the back of strong consumer and industrial demand as well as lower inventories.</li>  <li><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a> (CEMI) gains 9.9% and <a href=\"https://laohu8.com/S/NURO\">NeuroMetrix</a> (NURO) surges 33% amid discussions on message boards at Reddit and StockTwits.</li> </ul> Elsewhere, the Labor Department’s report, due at 8:30 a.m. ET, is expected to show the number of Americans filing new claims for unemployment benefits fell to 350K (from 360K) for the week ended July 17, amid rampant worker shortages. Investors have been closely following the health of the jobs market on which monetary policy hinges, especially after a series of higher inflation reading recently sparked fears about a sooner-than expected paring of policy support as the economy reopens.</p><p><blockquote><ul><li>滴滴出行(DIDI)在盘前交易中下跌3%，此前知情人士表示，中国监管机构正在考虑对这家网约车巨头在上个月备受争议的首次公开募股后实施严厉的、或许是前所未有的处罚。</li><li>德州仪器(TXN)第三季度销售和利润预测令分析师失望，股价下跌4.8%，巴克莱银行表示“前景平淡，在周期后期几乎没有什么可生存的了”。</li><li>AT&amp;T(T)股价上涨0.9%，由于更多美国人转向5G手机，该电信运营商第二季度每月电话费支付用户数量超出了分析师的预期。</li><li>陶氏化学(DOW)第二季度利润较第一季度翻倍，上涨1.3%，因消费者和工业需求强劲以及库存下降导致其用于塑料和包装的化学品价格上涨。</li><li><a href=\"https://laohu8.com/S/CEMI\">化学诊断学</a>(CEMI)上涨9.9%<a href=\"https://laohu8.com/S/NURO\">神经度量</a>在Reddit和StockTwits留言板上的讨论中，(NURO)飙升33%。</li></ul>在其他地方，劳工部将于美国东部时间上午8:30发布的报告预计将显示，由于工人严重短缺，截至7月17日当周，美国新申请失业救济的人数从36万降至35万。投资者一直在密切关注货币政策所依赖的就业市场的健康状况，特别是在最近一系列较高的通胀数据引发了人们对经济重新开放时政策支持将比预期更早削减的担忧之后。</blockquote></p><p> Bitcoin briefly rose above $32,000 after getting a boost from Elon Musk, who said his space exploration company SpaceX owns the digital token.</p><p><blockquote>在获得埃隆·马斯克(Elon Musk)的提振后，比特币股价短暂升破32,000美元，埃隆·马斯克表示，他的太空探索公司SpaceX拥有该数字代币。</blockquote></p><p> In commodities oil hung on to most of Wednesday's sharp price rise, its biggest one-day gain in three months. Brent crude futures were last 0.4% softer at $71.94 a barrel, but had gained more than 4% on Wednesday. Gold was steady at $1,801 an ounce and cryptocurrencies were firm after bouncing from lows when Tesla boss Elon Musk said the carmaker would likely restart accepting bitcoin payments after due diligence on its energy use.</p><p><blockquote>大宗商品方面，石油延续了周三价格大幅上涨的大部分时间，创下三个月来最大单日涨幅。布伦特原油期货最近下跌0.4%，至每桶71.94美元，但周三上涨超过4%。金价稳定在每盎司1,801美元，加密货币在从低点反弹后坚挺，当时特斯拉老板Elon Musk表示，在对其能源使用进行尽职调查后，该汽车制造商可能会重新开始接受比特币付款。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday<blockquote>周四美国市场开盘前的营收</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-22 19:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Julr&nbsp;22)&nbsp;Stock futures advanced on Thursday, with investors looking to earnings and data for impetus to extend a 2-day rally that wiped out losses sustained during the worst trading day of 2021.</p><p><blockquote>（7月22日）股指期货周四上涨，投资者寻求收益和数据的动力，以延续两天的涨势，抹去了2021年最糟糕交易日的跌幅。</blockquote></p><p> At 7:54 a.m. ET, Dow E-minis were up 47 points, or 0.14%, S&amp;P 500 E-minis were up 6.5&nbsp;points, or 0.15% and Nasdaq 100 E-minis rose 28.75 points, or 0.19%.&nbsp;</p><p><blockquote>截至美国东部时间上午7:54，道指E-minis上涨47点，涨幅0.14%，标普500 E-minis上涨6.5点，涨幅0.15%，纳斯达克100 E-minis上涨28.75点，涨幅0.19%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6f0ee7363c9fe8efde482515ffff79ac\" tg-width=\"1242\" tg-height=\"538\" referrerpolicy=\"no-referrer\">The turnaround from the Monday selloff shows “corporations have been very resilient through all this,”&nbsp;David Mazza, Direxion head of product, said on Bloomberg Television. “Earnings estimates are quite remarkable, probably some of the best on record. Even through all this, we have central-bank liquidity remaining very abundant, economic growth being robust.”</p><p><blockquote>Direxion产品主管David Mazza在彭博电视台表示，周一抛售的好转表明“企业在这一切中表现得非常有弹性”。“盈利预期相当出色，可能是有记录以来最好的之一。尽管如此，我们的央行流动性仍然非常充裕，经济增长强劲。”</blockquote></p><p> Energy and mega-cap tech stocks gained ahead of a new batch of earnings reports, the latest initial claims data and the first ECB meeting to incorporate the bank's new strategic review.&nbsp;Energy stocks Chevron Corp, Exxon Mobil, Schlumberger NV, Occidental Petroleum and Marathon Petroleum Corp climbed between 0.1% and 1%, tracking crude prices.</p><p><blockquote>在新一批收益报告、最新的首次申请失业救济数据以及欧洲央行首次会议纳入该行新的战略评估之前，能源股和大型科技股上涨。能源股雪佛龙公司、埃克森美孚公司、斯伦贝谢公司、西方石油公司和马拉松石油公司上涨0.1%至1%，跟踪原油价格。</blockquote></p><p> Some other notable pre-market movers:</p><p><blockquote>其他一些值得注意的盘前推动者：</blockquote></p><p> <ul>  <li>Didi Global (DIDI) drops 3% in&nbsp;premarket&nbsp;trading after people familiar with the matter said Chinese regulators are considering serious, perhaps unprecedented, penalties for for the ride-hailing giant after its controversial initial public offering last month.</li>  <li>Texas Instruments (TXN) drops 4.8% after third-quarter sales and profit forecasts left analysts disappointed, with Barclays saying the “flat outlook leaves little to live for this late in the cycle.”</li>  <li>AT&amp;T (T) added 0.9% as the telecom operator beat analysts’ estimates for monthly phone bill paying subscriber additions in the second quarter, fueled by more Americans converting to 5G phones.</li>  <li>Dow (DOW) rose 1.3% after its second-quarter profit doubled from the first, as prices for its chemicals used in plastics and packaging rose on the back of strong consumer and industrial demand as well as lower inventories.</li>  <li><a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a> (CEMI) gains 9.9% and <a href=\"https://laohu8.com/S/NURO\">NeuroMetrix</a> (NURO) surges 33% amid discussions on message boards at Reddit and StockTwits.</li> </ul> Elsewhere, the Labor Department’s report, due at 8:30 a.m. ET, is expected to show the number of Americans filing new claims for unemployment benefits fell to 350K (from 360K) for the week ended July 17, amid rampant worker shortages. Investors have been closely following the health of the jobs market on which monetary policy hinges, especially after a series of higher inflation reading recently sparked fears about a sooner-than expected paring of policy support as the economy reopens.</p><p><blockquote><ul><li>滴滴出行(DIDI)在盘前交易中下跌3%，此前知情人士表示，中国监管机构正在考虑对这家网约车巨头在上个月备受争议的首次公开募股后实施严厉的、或许是前所未有的处罚。</li><li>德州仪器(TXN)第三季度销售和利润预测令分析师失望，股价下跌4.8%，巴克莱银行表示“前景平淡，在周期后期几乎没有什么可生存的了”。</li><li>AT&amp;T(T)股价上涨0.9%，由于更多美国人转向5G手机，该电信运营商第二季度每月电话费支付用户数量超出了分析师的预期。</li><li>陶氏化学(DOW)第二季度利润较第一季度翻倍，上涨1.3%，因消费者和工业需求强劲以及库存下降导致其用于塑料和包装的化学品价格上涨。</li><li><a href=\"https://laohu8.com/S/CEMI\">化学诊断学</a>(CEMI)上涨9.9%<a href=\"https://laohu8.com/S/NURO\">神经度量</a>在Reddit和StockTwits留言板上的讨论中，(NURO)飙升33%。</li></ul>在其他地方，劳工部将于美国东部时间上午8:30发布的报告预计将显示，由于工人严重短缺，截至7月17日当周，美国新申请失业救济的人数从36万降至35万。投资者一直在密切关注货币政策所依赖的就业市场的健康状况，特别是在最近一系列较高的通胀数据引发了人们对经济重新开放时政策支持将比预期更早削减的担忧之后。</blockquote></p><p> Bitcoin briefly rose above $32,000 after getting a boost from Elon Musk, who said his space exploration company SpaceX owns the digital token.</p><p><blockquote>在获得埃隆·马斯克(Elon Musk)的提振后，比特币股价短暂升破32,000美元，埃隆·马斯克表示，他的太空探索公司SpaceX拥有该数字代币。</blockquote></p><p> In commodities oil hung on to most of Wednesday's sharp price rise, its biggest one-day gain in three months. Brent crude futures were last 0.4% softer at $71.94 a barrel, but had gained more than 4% on Wednesday. Gold was steady at $1,801 an ounce and cryptocurrencies were firm after bouncing from lows when Tesla boss Elon Musk said the carmaker would likely restart accepting bitcoin payments after due diligence on its energy use.</p><p><blockquote>大宗商品方面，石油延续了周三价格大幅上涨的大部分时间，创下三个月来最大单日涨幅。布伦特原油期货最近下跌0.4%，至每桶71.94美元，但周三上涨超过4%。金价稳定在每盎司1,801美元，加密货币在从低点反弹后坚挺，当时特斯拉老板Elon Musk表示，在对其能源使用进行尽职调查后，该汽车制造商可能会重新开始接受比特币付款。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127427732","content_text":"(Julr 22) Stock futures advanced on Thursday, with investors looking to earnings and data for impetus to extend a 2-day rally that wiped out losses sustained during the worst trading day of 2021.\nAt 7:54 a.m. ET, Dow E-minis were up 47 points, or 0.14%, S&P 500 E-minis were up 6.5 points, or 0.15% and Nasdaq 100 E-minis rose 28.75 points, or 0.19%. \nThe turnaround from the Monday selloff shows “corporations have been very resilient through all this,” David Mazza, Direxion head of product, said on Bloomberg Television. “Earnings estimates are quite remarkable, probably some of the best on record. Even through all this, we have central-bank liquidity remaining very abundant, economic growth being robust.”\nEnergy and mega-cap tech stocks gained ahead of a new batch of earnings reports, the latest initial claims data and the first ECB meeting to incorporate the bank's new strategic review. Energy stocks Chevron Corp, Exxon Mobil, Schlumberger NV, Occidental Petroleum and Marathon Petroleum Corp climbed between 0.1% and 1%, tracking crude prices.\nSome other notable pre-market movers:\n\nDidi Global (DIDI) drops 3% in premarket trading after people familiar with the matter said Chinese regulators are considering serious, perhaps unprecedented, penalties for for the ride-hailing giant after its controversial initial public offering last month.\nTexas Instruments (TXN) drops 4.8% after third-quarter sales and profit forecasts left analysts disappointed, with Barclays saying the “flat outlook leaves little to live for this late in the cycle.”\nAT&T (T) added 0.9% as the telecom operator beat analysts’ estimates for monthly phone bill paying subscriber additions in the second quarter, fueled by more Americans converting to 5G phones.\nDow (DOW) rose 1.3% after its second-quarter profit doubled from the first, as prices for its chemicals used in plastics and packaging rose on the back of strong consumer and industrial demand as well as lower inventories.\nChembio Diagnostics (CEMI) gains 9.9% and NeuroMetrix (NURO) surges 33% amid discussions on message boards at Reddit and StockTwits.\n\nElsewhere, the Labor Department’s report, due at 8:30 a.m. ET, is expected to show the number of Americans filing new claims for unemployment benefits fell to 350K (from 360K) for the week ended July 17, amid rampant worker shortages. Investors have been closely following the health of the jobs market on which monetary policy hinges, especially after a series of higher inflation reading recently sparked fears about a sooner-than expected paring of policy support as the economy reopens.\nBitcoin briefly rose above $32,000 after getting a boost from Elon Musk, who said his space exploration company SpaceX owns the digital token.\nIn commodities oil hung on to most of Wednesday's sharp price rise, its biggest one-day gain in three months. Brent crude futures were last 0.4% softer at $71.94 a barrel, but had gained more than 4% on Wednesday. Gold was steady at $1,801 an ounce and cryptocurrencies were firm after bouncing from lows when Tesla boss Elon Musk said the carmaker would likely restart accepting bitcoin payments after due diligence on its energy use.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,"SPY":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178602847,"gmtCreate":1626806336889,"gmtModify":1633770876236,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Let’s go&nbsp;","listText":"Let’s go&nbsp;","text":"Let’s go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178602847","repostId":"2152657163","repostType":4,"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170278050,"gmtCreate":1626439688670,"gmtModify":1633926755830,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/170278050","repostId":"1126115240","repostType":4,"repost":{"id":"1126115240","kind":"news","pubTimestamp":1626439254,"share":"https://www.laohu8.com/m/news/1126115240?lang=zh_CN&edition=full","pubTime":"2021-07-16 20:40","market":"us","language":"en","title":"U.S. retail sales unexpectedly rise in June<blockquote>美国6月零售销售意外上升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126115240","media":"Reuters","summary":"WASHINGTON, July 16 (Reuters) - U.S. retail sales unexpectedly increased in June as demand for goods","content":"<p>WASHINGTON, July 16 (Reuters) - U.S. retail sales unexpectedly increased in June as demand for goods remained strong even as spending is shifting back to services, bolstering expectations that economic growth accelerated in the second quarter.</p><p><blockquote>路透华盛顿7月16日-美国6月零售销售意外增长，因尽管支出正在重新转向服务业，但商品需求依然强劲，提振了第二季经济增长加速的预期。</blockquote></p><p> Retail sales rebounded 0.6% last month, the Commerce Department said on Friday. Data for May was revised down to show sales falling 1.7% instead of declining 1.3% as previously reported.</p><p><blockquote>美国商务部周五表示，上个月零售额反弹0.6%。5月份的数据被下调，显示销售额下降1.7%，而不是之前报道的下降1.3%。</blockquote></p><p> Economists polled by Reuters had forecast retail sales dropping 0.4%. But shortages of motor vehicles because of a global semiconductor supply squeeze, which is undercutting production, are hampering sales of automobiles.</p><p><blockquote>路透社调查的经济学家此前预测零售额将下降0.4%。但由于全球半导体供应紧张导致汽车短缺，导致产量下降，阻碍了汽车销售。</blockquote></p><p> Sales of some household appliances have also been impacted by the chip shortage.</p><p><blockquote>部分家用电器的销售也受到芯片短缺的冲击。</blockquote></p><p> “We expect supply issues and dwindling auto inventories to continue to limit auto sales in the coming months,” said Veronica Clark, an economist at Citigroup in New York.</p><p><blockquote>花旗集团驻纽约经济学家Veronica Clark表示：“我们预计供应问题和汽车库存减少将继续限制未来几个月的汽车销售。”</blockquote></p><p> Demand shifted to goods like electronics and motor vehicles during the pandemic as millions of people worked from home, took online classes and avoided public transportation.</p><p><blockquote>在疫情期间，随着数百万人在家工作、参加在线课程并避免乘坐公共交通工具，需求转向了电子产品和机动车辆等商品。</blockquote></p><p> Spending is now rotating back to services like travel and entertainment, with at least 160 million Americans fully vaccinated against COVID-19. Retail sales are mostly goods, with services such as healthcare, education, travel and hotel accommodation make the remaining portion of consumer spending.</p><p><blockquote>支出现在正在转向旅游和娱乐等服务，至少有1.6亿美国人完全接种了COVID-19疫苗。零售额主要是商品，医疗保健、教育、旅游和酒店住宿等服务占消费者支出的其余部分。</blockquote></p><p> Restaurants and bars are the only services category in the retail sales report.</p><p><blockquote>餐馆和酒吧是零售销售报告中唯一的服务类别。</blockquote></p><p> Excluding automobiles, gasoline, building materials and food services, retail sales increased 1.1% last month after a downwardly revised 1.4% decrease in May. These so-called core retail sales correspond most closely with the consumer spending component of gross domestic product. They were previously estimated to have dropped 0.7% in May.</p><p><blockquote>不包括汽车、汽油、建筑材料和食品服务，零售额在5月份下调1.4%后，上月增长1.1%。这些所谓的核心零售额与国内生产总值中的消费者支出部分最为接近。此前估计5月份下降了0.7%。</blockquote></p><p> “With the economy re-opening, services spending has begun to pick up and could pull some spending away from goods toward some services that are not captured in the retail sales report,” Kevin Cummins, chief U.S. economist at NatWest Markets in Stamford, Connecticut.</p><p><blockquote>康涅狄格州斯坦福德NatWest Markets首席美国经济学家凯文·卡明斯(Kevin Cummins)表示：“随着经济重新开放，服务支出已开始回升，可能会将部分支出从商品转向零售销售报告中未包含的一些服务。”</blockquote></p><p> Economists expect consumer spending, which accounts for more than two-thirds of U.S. economic activity, logged double-digit growth in the second quarter. Consumer spending grew at an 11.4% annualized rate in the first quarter.</p><p><blockquote>经济学家预计，占美国经济活动三分之二以上的消费者支出将在第二季度录得两位数增长。第一季度消费者支出年化增长率为11.4%。</blockquote></p><p> Households accumulated at least $2.5 trillion in excess savings during the pandemic, which is expected to drive spending this year and beyond. From July through December some households will receive income under the expanded Child Tax Credit program, which will soften the blow of an early termination of government-funded unemployment benefits at least 24 states.</p><p><blockquote>在疫情期间，家庭积累了至少2.5万亿美元的超额储蓄，预计这将推动今年及以后的支出。从7月到12月，一些家庭将根据扩大的儿童税收抵免计划获得收入，这将减轻至少24个州提前终止政府资助的失业救济金的打击。</blockquote></p><p> Gross domestic product growth estimates for this quarter are around a 9% rate, which would be an acceleration from the 6.4% pace notched in the first quarter. Economists believe the economy could achieve growth of at least 7% this year. That would be the fastest growth since 1984. The economy contracted 3.5% in 2020, its worst performance in 74 years.</p><p><blockquote>预计本季度国内生产总值增长率约为9%，较第一季度的6.4%有所加快。经济学家认为，今年经济至少可以实现7%的增长。这将是自1984年以来最快的增长。2020年经济萎缩3.5%，为74年来最差表现。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. retail sales unexpectedly rise in June<blockquote>美国6月零售销售意外上升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. retail sales unexpectedly rise in June<blockquote>美国6月零售销售意外上升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-16 20:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>WASHINGTON, July 16 (Reuters) - U.S. retail sales unexpectedly increased in June as demand for goods remained strong even as spending is shifting back to services, bolstering expectations that economic growth accelerated in the second quarter.</p><p><blockquote>路透华盛顿7月16日-美国6月零售销售意外增长，因尽管支出正在重新转向服务业，但商品需求依然强劲，提振了第二季经济增长加速的预期。</blockquote></p><p> Retail sales rebounded 0.6% last month, the Commerce Department said on Friday. Data for May was revised down to show sales falling 1.7% instead of declining 1.3% as previously reported.</p><p><blockquote>美国商务部周五表示，上个月零售额反弹0.6%。5月份的数据被下调，显示销售额下降1.7%，而不是之前报道的下降1.3%。</blockquote></p><p> Economists polled by Reuters had forecast retail sales dropping 0.4%. But shortages of motor vehicles because of a global semiconductor supply squeeze, which is undercutting production, are hampering sales of automobiles.</p><p><blockquote>路透社调查的经济学家此前预测零售额将下降0.4%。但由于全球半导体供应紧张导致汽车短缺，导致产量下降，阻碍了汽车销售。</blockquote></p><p> Sales of some household appliances have also been impacted by the chip shortage.</p><p><blockquote>部分家用电器的销售也受到芯片短缺的冲击。</blockquote></p><p> “We expect supply issues and dwindling auto inventories to continue to limit auto sales in the coming months,” said Veronica Clark, an economist at Citigroup in New York.</p><p><blockquote>花旗集团驻纽约经济学家Veronica Clark表示：“我们预计供应问题和汽车库存减少将继续限制未来几个月的汽车销售。”</blockquote></p><p> Demand shifted to goods like electronics and motor vehicles during the pandemic as millions of people worked from home, took online classes and avoided public transportation.</p><p><blockquote>在疫情期间，随着数百万人在家工作、参加在线课程并避免乘坐公共交通工具，需求转向了电子产品和机动车辆等商品。</blockquote></p><p> Spending is now rotating back to services like travel and entertainment, with at least 160 million Americans fully vaccinated against COVID-19. Retail sales are mostly goods, with services such as healthcare, education, travel and hotel accommodation make the remaining portion of consumer spending.</p><p><blockquote>支出现在正在转向旅游和娱乐等服务，至少有1.6亿美国人完全接种了COVID-19疫苗。零售额主要是商品，医疗保健、教育、旅游和酒店住宿等服务占消费者支出的其余部分。</blockquote></p><p> Restaurants and bars are the only services category in the retail sales report.</p><p><blockquote>餐馆和酒吧是零售销售报告中唯一的服务类别。</blockquote></p><p> Excluding automobiles, gasoline, building materials and food services, retail sales increased 1.1% last month after a downwardly revised 1.4% decrease in May. These so-called core retail sales correspond most closely with the consumer spending component of gross domestic product. They were previously estimated to have dropped 0.7% in May.</p><p><blockquote>不包括汽车、汽油、建筑材料和食品服务，零售额在5月份下调1.4%后，上月增长1.1%。这些所谓的核心零售额与国内生产总值中的消费者支出部分最为接近。此前估计5月份下降了0.7%。</blockquote></p><p> “With the economy re-opening, services spending has begun to pick up and could pull some spending away from goods toward some services that are not captured in the retail sales report,” Kevin Cummins, chief U.S. economist at NatWest Markets in Stamford, Connecticut.</p><p><blockquote>康涅狄格州斯坦福德NatWest Markets首席美国经济学家凯文·卡明斯(Kevin Cummins)表示：“随着经济重新开放，服务支出已开始回升，可能会将部分支出从商品转向零售销售报告中未包含的一些服务。”</blockquote></p><p> Economists expect consumer spending, which accounts for more than two-thirds of U.S. economic activity, logged double-digit growth in the second quarter. Consumer spending grew at an 11.4% annualized rate in the first quarter.</p><p><blockquote>经济学家预计，占美国经济活动三分之二以上的消费者支出将在第二季度录得两位数增长。第一季度消费者支出年化增长率为11.4%。</blockquote></p><p> Households accumulated at least $2.5 trillion in excess savings during the pandemic, which is expected to drive spending this year and beyond. From July through December some households will receive income under the expanded Child Tax Credit program, which will soften the blow of an early termination of government-funded unemployment benefits at least 24 states.</p><p><blockquote>在疫情期间，家庭积累了至少2.5万亿美元的超额储蓄，预计这将推动今年及以后的支出。从7月到12月，一些家庭将根据扩大的儿童税收抵免计划获得收入，这将减轻至少24个州提前终止政府资助的失业救济金的打击。</blockquote></p><p> Gross domestic product growth estimates for this quarter are around a 9% rate, which would be an acceleration from the 6.4% pace notched in the first quarter. Economists believe the economy could achieve growth of at least 7% this year. That would be the fastest growth since 1984. The economy contracted 3.5% in 2020, its worst performance in 74 years.</p><p><blockquote>预计本季度国内生产总值增长率约为9%，较第一季度的6.4%有所加快。经济学家认为，今年经济至少可以实现7%的增长。这将是自1984年以来最快的增长。2020年经济萎缩3.5%，为74年来最差表现。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/usa-economy/wrapup-1-u-s-retail-sales-unexpectedly-rise-in-june-idUSL1N2OR2ST\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯"},"source_url":"https://www.reuters.com/article/usa-economy/wrapup-1-u-s-retail-sales-unexpectedly-rise-in-june-idUSL1N2OR2ST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126115240","content_text":"WASHINGTON, July 16 (Reuters) - U.S. retail sales unexpectedly increased in June as demand for goods remained strong even as spending is shifting back to services, bolstering expectations that economic growth accelerated in the second quarter.\nRetail sales rebounded 0.6% last month, the Commerce Department said on Friday. Data for May was revised down to show sales falling 1.7% instead of declining 1.3% as previously reported.\nEconomists polled by Reuters had forecast retail sales dropping 0.4%. But shortages of motor vehicles because of a global semiconductor supply squeeze, which is undercutting production, are hampering sales of automobiles.\nSales of some household appliances have also been impacted by the chip shortage.\n“We expect supply issues and dwindling auto inventories to continue to limit auto sales in the coming months,” said Veronica Clark, an economist at Citigroup in New York.\nDemand shifted to goods like electronics and motor vehicles during the pandemic as millions of people worked from home, took online classes and avoided public transportation.\nSpending is now rotating back to services like travel and entertainment, with at least 160 million Americans fully vaccinated against COVID-19. Retail sales are mostly goods, with services such as healthcare, education, travel and hotel accommodation make the remaining portion of consumer spending.\nRestaurants and bars are the only services category in the retail sales report.\nExcluding automobiles, gasoline, building materials and food services, retail sales increased 1.1% last month after a downwardly revised 1.4% decrease in May. These so-called core retail sales correspond most closely with the consumer spending component of gross domestic product. They were previously estimated to have dropped 0.7% in May.\n“With the economy re-opening, services spending has begun to pick up and could pull some spending away from goods toward some services that are not captured in the retail sales report,” Kevin Cummins, chief U.S. economist at NatWest Markets in Stamford, Connecticut.\nEconomists expect consumer spending, which accounts for more than two-thirds of U.S. economic activity, logged double-digit growth in the second quarter. Consumer spending grew at an 11.4% annualized rate in the first quarter.\nHouseholds accumulated at least $2.5 trillion in excess savings during the pandemic, which is expected to drive spending this year and beyond. From July through December some households will receive income under the expanded Child Tax Credit program, which will soften the blow of an early termination of government-funded unemployment benefits at least 24 states.\nGross domestic product growth estimates for this quarter are around a 9% rate, which would be an acceleration from the 6.4% pace notched in the first quarter. Economists believe the economy could achieve growth of at least 7% this year. That would be the fastest growth since 1984. The economy contracted 3.5% in 2020, its worst performance in 74 years.","news_type":1,"symbols_score_info":{".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":538,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144642339,"gmtCreate":1626286002321,"gmtModify":1631888350211,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Cmon AMC go go","listText":"Cmon AMC go go","text":"Cmon AMC go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144642339","repostId":"2151142915","repostType":4,"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144646224,"gmtCreate":1626285911968,"gmtModify":1633928257614,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok nice&nbsp;","listText":"Ok nice&nbsp;","text":"Ok nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144646224","repostId":"1103407312","repostType":4,"repost":{"id":"1103407312","kind":"news","pubTimestamp":1626275222,"share":"https://www.laohu8.com/m/news/1103407312?lang=zh_CN&edition=full","pubTime":"2021-07-14 23:07","market":"us","language":"en","title":"Microsoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103407312","media":"Reuters","summary":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-b","content":"<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p><p><blockquote>（路透社）-微软公司周三表示，将提供其Windows操作系统作为基于云的服务，旨在使从更广泛的设备更容易访问需要Windows的商业应用程序。</blockquote></p><p> Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p><p><blockquote>这项服务将被称为Windows 365，将于8月2日推出，其工作方式有点像购买一台新的Windows PC：企业或学校将选择他们希望为新机器提供多少计算能力、内存和存储空间。</blockquote></p><p> But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p><p><blockquote>但是，员工或学生将通过现有的PC、Mac、iPhone、Android手机或Chromebook访问云中的操作系统，而不是等待物理机器到达邮件，只要它有一个与广泛使用的互联网标准HTML 5兼容的网络浏览器。</blockquote></p><p> The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p><p><blockquote>基于云的版本是为了响应客户的反馈而创建的，这些客户希望员工和学生无论身在何处都能更快、更轻松地访问PC。</blockquote></p><p> \"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p><p><blockquote>公司副总裁Jared Spataro表示：“我们将向混合工作的转变定义为工作方式、时间和地点的真正灵活性。随着人们开始尝试，这确实是我们在世界各地看到的发展模式。”微软365软件总裁。</blockquote></p><p> The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p><p><blockquote>这项服务类似于所谓的“虚拟”和“远程”桌面，这些桌面已经存在了几十年，但需要复杂的IT部门来设置和管理。这些成本也可能是不可预测的，因为它们是基于桌面的使用量。</blockquote></p><p> Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p><p><blockquote>微软希望Windows 365技术对于小企业主或小型学校来说足够容易引入，而无需大型IT部门，并根据每台虚拟计算机的大小提供可预测的每月账单。</blockquote></p><p> Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p><p><blockquote>Forrester Research分析师Andrew Hewitt表示，面对来自苹果公司和Alphabet谷歌操作系统的激烈竞争，此举将有助于微软捍卫其主导市场份额，这些操作系统更易于学校和企业管理。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-14 23:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p><p><blockquote>（路透社）-微软公司周三表示，将提供其Windows操作系统作为基于云的服务，旨在使从更广泛的设备更容易访问需要Windows的商业应用程序。</blockquote></p><p> Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p><p><blockquote>这项服务将被称为Windows 365，将于8月2日推出，其工作方式有点像购买一台新的Windows PC：企业或学校将选择他们希望为新机器提供多少计算能力、内存和存储空间。</blockquote></p><p> But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p><p><blockquote>但是，员工或学生将通过现有的PC、Mac、iPhone、Android手机或Chromebook访问云中的操作系统，而不是等待物理机器到达邮件，只要它有一个与广泛使用的互联网标准HTML 5兼容的网络浏览器。</blockquote></p><p> The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p><p><blockquote>基于云的版本是为了响应客户的反馈而创建的，这些客户希望员工和学生无论身在何处都能更快、更轻松地访问PC。</blockquote></p><p> \"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p><p><blockquote>公司副总裁Jared Spataro表示：“我们将向混合工作的转变定义为工作方式、时间和地点的真正灵活性。随着人们开始尝试，这确实是我们在世界各地看到的发展模式。”微软365软件总裁。</blockquote></p><p> The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p><p><blockquote>这项服务类似于所谓的“虚拟”和“远程”桌面，这些桌面已经存在了几十年，但需要复杂的IT部门来设置和管理。这些成本也可能是不可预测的，因为它们是基于桌面的使用量。</blockquote></p><p> Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p><p><blockquote>微软希望Windows 365技术对于小企业主或小型学校来说足够容易引入，而无需大型IT部门，并根据每台虚拟计算机的大小提供可预测的每月账单。</blockquote></p><p> Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p><p><blockquote>Forrester Research分析师Andrew Hewitt表示，面对来自苹果公司和Alphabet谷歌操作系统的激烈竞争，此举将有助于微软捍卫其主导市场份额，这些操作系统更易于学校和企业管理。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103407312","content_text":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.\nWindows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.\nBut instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.\nThe cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.\n\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.\nThe service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.\nMicrosoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.\nAndrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142901038,"gmtCreate":1626109622624,"gmtModify":1633930022286,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Pls like tyvm 😊","listText":"Pls like tyvm 😊","text":"Pls like tyvm 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142901038","repostId":"1105917995","repostType":4,"isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141106148,"gmtCreate":1625840851484,"gmtModify":1633936797009,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576835084140349","authorIdStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/141106148","repostId":"1173374462","repostType":4,"repost":{"id":"1173374462","kind":"news","pubTimestamp":1625840008,"share":"https://www.laohu8.com/m/news/1173374462?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:13","market":"us","language":"en","title":"Meme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1173374462","media":"Thestreet","summary":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment","content":"<p>Gamestop&nbsp;(<b>GME</b>)&nbsp;made some investors rich… and then it broke many more. Investing in AMC Entertainment&nbsp;(<b>AMC</b>)&nbsp;did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.</p><p><blockquote>游戏驿站(<b>GME</b>）让一些投资者变得富有……然后又破产了更多。投资AMC院线（<b>AMC</b>）做了完全相同的事情。这两只股票即使不是失败的企业，也至少代表了陷入困境的企业；甚至在大流行之前就努力跟上新经济的公司就关闭了大部分新经济。然而，在过去的几个月里，他们公布了市场上一些最不稳定的收益和损失。</blockquote></p><p> How?</p><p><blockquote>如何？</blockquote></p><p> It’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?</p><p><blockquote>这取决于Real Money的Timothy Collins评级市场的“模因股票夸张”。但是，他写道，这真的与交易一直以来的运作方式有那么大的不同吗？</blockquote></p><p> Have you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?</p><p><blockquote>您是否真正想过“登月”或“信念购买”这两个短语，以及它们如何扰乱我们对公允价值的看法？</blockquote></p><p> \"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.</p><p><blockquote>“最初，我对继续使用‘去月球’这个词翻了个白眼，”柯林斯说。“例如，这不像‘强力买入，目标价为65美元’。‘登月’完全是任意的，可以进行解释，但话又说回来，当你仔细想想时，大多数关于估值的事情也是如此，”柯林斯写道。</blockquote></p><p> \"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.</p><p><blockquote>“例如，当分析师在一只股票上敲打桌子时，这与‘飞向月球’有什么不同？或者当有人说‘全押’时。他们真的全押了吗？他们是否兑现了所有资产，集中流动性，并尽可能购买每一股？可能不会。事实上，我会说绝对不是99.9999%的情况。当然，总有那么一个人，”柯林斯说。</blockquote></p><p> \"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"</p><p><blockquote>“但关键是，华尔街多年来一直是武断的。我们甚至不能有一个标准的评级系统。它是‘中性’还是‘持有’？说真的，我想持有只在你的范围中间的东西吗？不。”</blockquote></p><p> Collins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"</p><p><blockquote>柯林斯写道，“系统应该是‘买入’或‘卖出’。就是这样。黑或白。拥有或不拥有。”</blockquote></p><p> Assets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.</p><p><blockquote>像游戏驿站甚至加密货币这样的资产似乎只不过是纯粹的情绪在出售。投资者正在享受这些产品，这往往会导致价格飞涨。</blockquote></p><p> That’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.</p><p><blockquote>诚然，这很令人困惑。只是，在你举手之前，重要的是要记住股票市场总是至少有一点武断。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Thestreet</strong><span class=\"h-time small\">2021-07-09 22:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Gamestop&nbsp;(<b>GME</b>)&nbsp;made some investors rich… and then it broke many more. Investing in AMC Entertainment&nbsp;(<b>AMC</b>)&nbsp;did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.</p><p><blockquote>游戏驿站(<b>GME</b>）让一些投资者变得富有……然后又破产了更多。投资AMC院线（<b>AMC</b>）做了完全相同的事情。这两只股票即使不是失败的企业，也至少代表了陷入困境的企业；甚至在大流行之前就努力跟上新经济的公司就关闭了大部分新经济。然而，在过去的几个月里，他们公布了市场上一些最不稳定的收益和损失。</blockquote></p><p> How?</p><p><blockquote>如何？</blockquote></p><p> It’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?</p><p><blockquote>这取决于Real Money的Timothy Collins评级市场的“模因股票夸张”。但是，他写道，这真的与交易一直以来的运作方式有那么大的不同吗？</blockquote></p><p> Have you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?</p><p><blockquote>您是否真正想过“登月”或“信念购买”这两个短语，以及它们如何扰乱我们对公允价值的看法？</blockquote></p><p> \"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.</p><p><blockquote>“最初，我对继续使用‘去月球’这个词翻了个白眼，”柯林斯说。“例如，这不像‘强力买入，目标价为65美元’。‘登月’完全是任意的，可以进行解释，但话又说回来，当你仔细想想时，大多数关于估值的事情也是如此，”柯林斯写道。</blockquote></p><p> \"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.</p><p><blockquote>“例如，当分析师在一只股票上敲打桌子时，这与‘飞向月球’有什么不同？或者当有人说‘全押’时。他们真的全押了吗？他们是否兑现了所有资产，集中流动性，并尽可能购买每一股？可能不会。事实上，我会说绝对不是99.9999%的情况。当然，总有那么一个人，”柯林斯说。</blockquote></p><p> \"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"</p><p><blockquote>“但关键是，华尔街多年来一直是武断的。我们甚至不能有一个标准的评级系统。它是‘中性’还是‘持有’？说真的，我想持有只在你的范围中间的东西吗？不。”</blockquote></p><p> Collins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"</p><p><blockquote>柯林斯写道，“系统应该是‘买入’或‘卖出’。就是这样。黑或白。拥有或不拥有。”</blockquote></p><p> Assets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.</p><p><blockquote>像游戏驿站甚至加密货币这样的资产似乎只不过是纯粹的情绪在出售。投资者正在享受这些产品，这往往会导致价格飞涨。</blockquote></p><p> That’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.</p><p><blockquote>诚然，这很令人困惑。只是，在你举手之前，重要的是要记住股票市场总是至少有一点武断。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality\">Thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173374462","content_text":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment (AMC) did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.\nHow?\nIt’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?\nHave you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?\n\"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.\n\"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.\n\"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"\nCollins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"\nAssets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.\nThat’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.","news_type":1,"symbols_score_info":{"GME":0.9,"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":892174124,"gmtCreate":1628646190368,"gmtModify":1633745432252,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","listText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","text":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/892174124","repostId":"1185123318","repostType":4,"isVote":1,"tweetType":1,"viewCount":2937,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141106148,"gmtCreate":1625840851484,"gmtModify":1633936797009,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/141106148","repostId":"1173374462","repostType":4,"repost":{"id":"1173374462","kind":"news","pubTimestamp":1625840008,"share":"https://www.laohu8.com/m/news/1173374462?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:13","market":"us","language":"en","title":"Meme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1173374462","media":"Thestreet","summary":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment","content":"<p>Gamestop&nbsp;(<b>GME</b>)&nbsp;made some investors rich… and then it broke many more. Investing in AMC Entertainment&nbsp;(<b>AMC</b>)&nbsp;did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.</p><p><blockquote>游戏驿站(<b>GME</b>）让一些投资者变得富有……然后又破产了更多。投资AMC院线（<b>AMC</b>）做了完全相同的事情。这两只股票即使不是失败的企业，也至少代表了陷入困境的企业；甚至在大流行之前就努力跟上新经济的公司就关闭了大部分新经济。然而，在过去的几个月里，他们公布了市场上一些最不稳定的收益和损失。</blockquote></p><p> How?</p><p><blockquote>如何？</blockquote></p><p> It’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?</p><p><blockquote>这取决于Real Money的Timothy Collins评级市场的“模因股票夸张”。但是，他写道，这真的与交易一直以来的运作方式有那么大的不同吗？</blockquote></p><p> Have you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?</p><p><blockquote>您是否真正想过“登月”或“信念购买”这两个短语，以及它们如何扰乱我们对公允价值的看法？</blockquote></p><p> \"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.</p><p><blockquote>“最初，我对继续使用‘去月球’这个词翻了个白眼，”柯林斯说。“例如，这不像‘强力买入，目标价为65美元’。‘登月’完全是任意的，可以进行解释，但话又说回来，当你仔细想想时，大多数关于估值的事情也是如此，”柯林斯写道。</blockquote></p><p> \"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.</p><p><blockquote>“例如，当分析师在一只股票上敲打桌子时，这与‘飞向月球’有什么不同？或者当有人说‘全押’时。他们真的全押了吗？他们是否兑现了所有资产，集中流动性，并尽可能购买每一股？可能不会。事实上，我会说绝对不是99.9999%的情况。当然，总有那么一个人，”柯林斯说。</blockquote></p><p> \"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"</p><p><blockquote>“但关键是，华尔街多年来一直是武断的。我们甚至不能有一个标准的评级系统。它是‘中性’还是‘持有’？说真的，我想持有只在你的范围中间的东西吗？不。”</blockquote></p><p> Collins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"</p><p><blockquote>柯林斯写道，“系统应该是‘买入’或‘卖出’。就是这样。黑或白。拥有或不拥有。”</blockquote></p><p> Assets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.</p><p><blockquote>像游戏驿站甚至加密货币这样的资产似乎只不过是纯粹的情绪在出售。投资者正在享受这些产品，这往往会导致价格飞涨。</blockquote></p><p> That’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.</p><p><blockquote>诚然，这很令人困惑。只是，在你举手之前，重要的是要记住股票市场总是至少有一点武断。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stocks Like GameStop and AMC Reflect Market Reality<blockquote>游戏驿站和AMC等模因股票反映了市场现实</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Thestreet</strong><span class=\"h-time small\">2021-07-09 22:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Gamestop&nbsp;(<b>GME</b>)&nbsp;made some investors rich… and then it broke many more. Investing in AMC Entertainment&nbsp;(<b>AMC</b>)&nbsp;did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.</p><p><blockquote>游戏驿站(<b>GME</b>）让一些投资者变得富有……然后又破产了更多。投资AMC院线（<b>AMC</b>）做了完全相同的事情。这两只股票即使不是失败的企业，也至少代表了陷入困境的企业；甚至在大流行之前就努力跟上新经济的公司就关闭了大部分新经济。然而，在过去的几个月里，他们公布了市场上一些最不稳定的收益和损失。</blockquote></p><p> How?</p><p><blockquote>如何？</blockquote></p><p> It’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?</p><p><blockquote>这取决于Real Money的Timothy Collins评级市场的“模因股票夸张”。但是，他写道，这真的与交易一直以来的运作方式有那么大的不同吗？</blockquote></p><p> Have you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?</p><p><blockquote>您是否真正想过“登月”或“信念购买”这两个短语，以及它们如何扰乱我们对公允价值的看法？</blockquote></p><p> \"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.</p><p><blockquote>“最初，我对继续使用‘去月球’这个词翻了个白眼，”柯林斯说。“例如，这不像‘强力买入，目标价为65美元’。‘登月’完全是任意的，可以进行解释，但话又说回来，当你仔细想想时，大多数关于估值的事情也是如此，”柯林斯写道。</blockquote></p><p> \"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.</p><p><blockquote>“例如，当分析师在一只股票上敲打桌子时，这与‘飞向月球’有什么不同？或者当有人说‘全押’时。他们真的全押了吗？他们是否兑现了所有资产，集中流动性，并尽可能购买每一股？可能不会。事实上，我会说绝对不是99.9999%的情况。当然，总有那么一个人，”柯林斯说。</blockquote></p><p> \"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"</p><p><blockquote>“但关键是，华尔街多年来一直是武断的。我们甚至不能有一个标准的评级系统。它是‘中性’还是‘持有’？说真的，我想持有只在你的范围中间的东西吗？不。”</blockquote></p><p> Collins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"</p><p><blockquote>柯林斯写道，“系统应该是‘买入’或‘卖出’。就是这样。黑或白。拥有或不拥有。”</blockquote></p><p> Assets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.</p><p><blockquote>像游戏驿站甚至加密货币这样的资产似乎只不过是纯粹的情绪在出售。投资者正在享受这些产品，这往往会导致价格飞涨。</blockquote></p><p> That’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.</p><p><blockquote>诚然，这很令人困惑。只是，在你举手之前，重要的是要记住股票市场总是至少有一点武断。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality\">Thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173374462","content_text":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment (AMC) did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.\nHow?\nIt’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?\nHave you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?\n\"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.\n\"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.\n\"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"\nCollins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"\nAssets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.\nThat’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.","news_type":1,"symbols_score_info":{"GME":0.9,"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158319095,"gmtCreate":1625128801917,"gmtModify":1631884665763,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"90% China market share but still unprofitable bizmodel currently, future is autonomous vehicle, if able to eliminate driver cost, will send this stock over the moon","listText":"90% China market share but still unprofitable bizmodel currently, future is autonomous vehicle, if able to eliminate driver cost, will send this stock over the moon","text":"90% China market share but still unprofitable bizmodel currently, future is autonomous vehicle, if able to eliminate driver cost, will send this stock over the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/158319095","repostId":"2148849816","repostType":4,"repost":{"id":"2148849816","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625126879,"share":"https://www.laohu8.com/m/news/2148849816?lang=zh_CN&edition=full","pubTime":"2021-07-01 16:07","market":"us","language":"en","title":"China's Didi to be added to FTSE's equity indexes on July 8<blockquote>中国滴滴将于7月8日纳入富时股票指数</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2148849816","media":"Tiger Newspress","summary":"Didi shares surged 6% in premarket trading on being added to FTSE's equity indexes on July 8.\n\nDidi ","content":"<p>Didi&nbsp;shares&nbsp;surged&nbsp;6%&nbsp;in premarket trading&nbsp;on&nbsp;being added to FTSE's equity indexes on July 8.</p><p><blockquote>滴滴于7月8日被纳入富时股票指数后，其股价在盘前交易中飙升6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/12d5f8e9fe3db529c401011e409d44e9\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> Didi Global Inc will be added to FTSE Russell's global equity indexes on July 8 in an expedited entry following Wednesday's U.S. stock market debut of the Chinese ride-hailing company, the index publisher said.</p><p><blockquote>指数发布者表示，滴滴全球公司将于7月8日被纳入富时罗素全球股票指数，这是继这家中国网约车公司周三在美国股市首次亮相后的快速进入。</blockquote></p><p> Didi shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.</p><p><blockquote>富时罗素在其网站上的一份声明中表示，滴滴股票将被纳入富时全球指数、富时全球大型股指数和富时新兴指数。</blockquote></p><p> The announcement came as Didi, backed by Japan's SoftBank Group Corp, rose slightly on its U.S. debut, valuing it at $68.49 billion, in the biggest U.S. listing by a Chinese company since 2014.</p><p><blockquote>这一消息发布之际，由日本软银集团支持的滴滴在美国首次亮相时小幅上涨，估值为684.9亿美元，这是自2014年以来中国公司在美国上市的规模最大的一次。</blockquote></p><p> Didi is also backed by technology companies Alibaba, Tencent and Uber.</p><p><blockquote>滴滴还得到了科技公司阿里巴巴-SW、腾讯控股和优步的支持。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Didi to be added to FTSE's equity indexes on July 8<blockquote>中国滴滴将于7月8日纳入富时股票指数</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Didi to be added to FTSE's equity indexes on July 8<blockquote>中国滴滴将于7月8日纳入富时股票指数</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-01 16:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Didi&nbsp;shares&nbsp;surged&nbsp;6%&nbsp;in premarket trading&nbsp;on&nbsp;being added to FTSE's equity indexes on July 8.</p><p><blockquote>滴滴于7月8日被纳入富时股票指数后，其股价在盘前交易中飙升6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/12d5f8e9fe3db529c401011e409d44e9\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> Didi Global Inc will be added to FTSE Russell's global equity indexes on July 8 in an expedited entry following Wednesday's U.S. stock market debut of the Chinese ride-hailing company, the index publisher said.</p><p><blockquote>指数发布者表示，滴滴全球公司将于7月8日被纳入富时罗素全球股票指数，这是继这家中国网约车公司周三在美国股市首次亮相后的快速进入。</blockquote></p><p> Didi shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.</p><p><blockquote>富时罗素在其网站上的一份声明中表示，滴滴股票将被纳入富时全球指数、富时全球大型股指数和富时新兴指数。</blockquote></p><p> The announcement came as Didi, backed by Japan's SoftBank Group Corp, rose slightly on its U.S. debut, valuing it at $68.49 billion, in the biggest U.S. listing by a Chinese company since 2014.</p><p><blockquote>这一消息发布之际，由日本软银集团支持的滴滴在美国首次亮相时小幅上涨，估值为684.9亿美元，这是自2014年以来中国公司在美国上市的规模最大的一次。</blockquote></p><p> Didi is also backed by technology companies Alibaba, Tencent and Uber.</p><p><blockquote>滴滴还得到了科技公司阿里巴巴-SW、腾讯控股和优步的支持。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148849816","content_text":"Didi shares surged 6% in premarket trading on being added to FTSE's equity indexes on July 8.\n\nDidi Global Inc will be added to FTSE Russell's global equity indexes on July 8 in an expedited entry following Wednesday's U.S. stock market debut of the Chinese ride-hailing company, the index publisher said.\nDidi shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.\nThe announcement came as Didi, backed by Japan's SoftBank Group Corp, rose slightly on its U.S. debut, valuing it at $68.49 billion, in the biggest U.S. listing by a Chinese company since 2014.\nDidi is also backed by technology companies Alibaba, Tencent and Uber.","news_type":1,"symbols_score_info":{"DIDI":0.9}},"isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883490547,"gmtCreate":1631261575289,"gmtModify":1632883582121,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Time is running out for market share","listText":"Time is running out for market share","text":"Time is running out for market share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/883490547","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://www.laohu8.com/m/news/1158877090?lang=zh_CN&edition=full","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-10 15:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801174817,"gmtCreate":1627493155939,"gmtModify":1633764458673,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Buy index and sleep well at night&nbsp;","listText":"Buy index and sleep well at night&nbsp;","text":"Buy index and sleep well at night","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/801174817","repostId":"2154918711","repostType":4,"isVote":1,"tweetType":1,"viewCount":3287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144646224,"gmtCreate":1626285911968,"gmtModify":1633928257614,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok nice&nbsp;","listText":"Ok nice&nbsp;","text":"Ok nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144646224","repostId":"1103407312","repostType":4,"repost":{"id":"1103407312","kind":"news","pubTimestamp":1626275222,"share":"https://www.laohu8.com/m/news/1103407312?lang=zh_CN&edition=full","pubTime":"2021-07-14 23:07","market":"us","language":"en","title":"Microsoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103407312","media":"Reuters","summary":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-b","content":"<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p><p><blockquote>（路透社）-微软公司周三表示，将提供其Windows操作系统作为基于云的服务，旨在使从更广泛的设备更容易访问需要Windows的商业应用程序。</blockquote></p><p> Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p><p><blockquote>这项服务将被称为Windows 365，将于8月2日推出，其工作方式有点像购买一台新的Windows PC：企业或学校将选择他们希望为新机器提供多少计算能力、内存和存储空间。</blockquote></p><p> But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p><p><blockquote>但是，员工或学生将通过现有的PC、Mac、iPhone、Android手机或Chromebook访问云中的操作系统，而不是等待物理机器到达邮件，只要它有一个与广泛使用的互联网标准HTML 5兼容的网络浏览器。</blockquote></p><p> The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p><p><blockquote>基于云的版本是为了响应客户的反馈而创建的，这些客户希望员工和学生无论身在何处都能更快、更轻松地访问PC。</blockquote></p><p> \"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p><p><blockquote>公司副总裁Jared Spataro表示：“我们将向混合工作的转变定义为工作方式、时间和地点的真正灵活性。随着人们开始尝试，这确实是我们在世界各地看到的发展模式。”微软365软件总裁。</blockquote></p><p> The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p><p><blockquote>这项服务类似于所谓的“虚拟”和“远程”桌面，这些桌面已经存在了几十年，但需要复杂的IT部门来设置和管理。这些成本也可能是不可预测的，因为它们是基于桌面的使用量。</blockquote></p><p> Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p><p><blockquote>微软希望Windows 365技术对于小企业主或小型学校来说足够容易引入，而无需大型IT部门，并根据每台虚拟计算机的大小提供可预测的每月账单。</blockquote></p><p> Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p><p><blockquote>Forrester Research分析师Andrew Hewitt表示，面对来自苹果公司和Alphabet谷歌操作系统的激烈竞争，此举将有助于微软捍卫其主导市场份额，这些操作系统更易于学校和企业管理。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to offer cloud-based version of Windows operating system<blockquote>微软将提供基于云的Windows操作系统版本</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-14 23:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p><p><blockquote>（路透社）-微软公司周三表示，将提供其Windows操作系统作为基于云的服务，旨在使从更广泛的设备更容易访问需要Windows的商业应用程序。</blockquote></p><p> Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p><p><blockquote>这项服务将被称为Windows 365，将于8月2日推出，其工作方式有点像购买一台新的Windows PC：企业或学校将选择他们希望为新机器提供多少计算能力、内存和存储空间。</blockquote></p><p> But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p><p><blockquote>但是，员工或学生将通过现有的PC、Mac、iPhone、Android手机或Chromebook访问云中的操作系统，而不是等待物理机器到达邮件，只要它有一个与广泛使用的互联网标准HTML 5兼容的网络浏览器。</blockquote></p><p> The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p><p><blockquote>基于云的版本是为了响应客户的反馈而创建的，这些客户希望员工和学生无论身在何处都能更快、更轻松地访问PC。</blockquote></p><p> \"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p><p><blockquote>公司副总裁Jared Spataro表示：“我们将向混合工作的转变定义为工作方式、时间和地点的真正灵活性。随着人们开始尝试，这确实是我们在世界各地看到的发展模式。”微软365软件总裁。</blockquote></p><p> The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p><p><blockquote>这项服务类似于所谓的“虚拟”和“远程”桌面，这些桌面已经存在了几十年，但需要复杂的IT部门来设置和管理。这些成本也可能是不可预测的，因为它们是基于桌面的使用量。</blockquote></p><p> Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p><p><blockquote>微软希望Windows 365技术对于小企业主或小型学校来说足够容易引入，而无需大型IT部门，并根据每台虚拟计算机的大小提供可预测的每月账单。</blockquote></p><p> Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p><p><blockquote>Forrester Research分析师Andrew Hewitt表示，面对来自苹果公司和Alphabet谷歌操作系统的激烈竞争，此举将有助于微软捍卫其主导市场份额，这些操作系统更易于学校和企业管理。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103407312","content_text":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.\nWindows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.\nBut instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.\nThe cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.\n\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.\nThe service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.\nMicrosoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.\nAndrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890001411,"gmtCreate":1628064152233,"gmtModify":1633753926691,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","listText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","text":"Pfizer slow and steady NVAX roller coaster rideChoose your poison","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890001411","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800668518,"gmtCreate":1627298877934,"gmtModify":1633766403651,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Fsly yeah","listText":"Fsly yeah","text":"Fsly yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/800668518","repostId":"2154931205","repostType":4,"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177236555,"gmtCreate":1627221210177,"gmtModify":1633767078890,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Like comment pls","listText":"Like comment pls","text":"Like comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177236555","repostId":"2153878189","repostType":4,"isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177236148,"gmtCreate":1627221165984,"gmtModify":1633767079360,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok like comment&nbsp;","listText":"Ok like comment&nbsp;","text":"Ok like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177236148","repostId":"1115106146","repostType":4,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}